- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01689649
A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy
26 april 2013 uppdaterad av: Johnson & Johnson Pte Ltd
Open Flexible Dose Optimisation Trial Assessing Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy Who Are Treatment Naive or Have Failed One Anti-Epileptic Drug Treatment in Monotherapy
The purpose of this dose optimization study is to assess tolerability and efficacy of topiramate monotherapy in recently diagnosed patients with epilepsy who are treatment naive or have failed one anti-epileptic drug (AED) treatment in monotherapy.
Studieöversikt
Detaljerad beskrivning
This is an open label (all people know the identity of the intervention), dose optimization trial to assess the tolerability and efficacy of topiramate as monotherapy in recently (within 5 years) diagnosed patients with epilepsy.
Treatment naive patients (patients who have never received the treatment before) and patients who failed on their first AED in monotherapy are allowed.
Failure is defined as a lack of efficacy and/or tolerability of that AED and the reason for failure is recorded by the physician.
A lack of efficacy is characterized when the patient has been treated with AED at target dose but the patient still has seizure.
Topiramate will first be titrated up to an initial target dose that will be reached after 4-6 weeks.
Further dose titration is guided by the clinical response of the individual patient, but the dose may not exceed a maximum of 400mg/day [9mg/kg/day for children].
If the patient uses an AED at entry, the AED will be fully tapered off over a period of 3 weeks, starting at the beginning of week 2, in order to have all patients on topiramate monotherapy at visit 3. Tapering the AED off may, however, extend this 3-week period if clinically indicated.
Visits will be performed at baseline and after 2, 4, 8, 12, 16 weeks.
The total duration for each patient in the study will be 4 months.
Studietyp
Interventionell
Inskrivning (Faktisk)
139
Fas
- Fas 4
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
5 år till 18 år (Barn, Vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Has been diagnosed with epilepsy within the past 5 years with Primary Generalized Tonic-Clonic (PGTC) seizures as well as partial onset seizures with or without secondary generalization
- Therapy naive, or being treated with their first anti-epileptic drug (AED) in monotherapy that fails in efficacy, tolerability, or both, and not in need of a combination AED therapy
- Informed Assent in children at least 7 years and older
Exclusion Criteria:
- Have pseudoseizures or the treatable cause of the seizures (eg, metabolic disorder, toxic exposure, active infection or neoplasia)
- Has any clinically relevant progressive or serious illness (eg, liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric, or metabolic disturbance)
- Pregnant or breast-feeding
- Has a history or suspicion of alcohol or drug abuse
- Must have on current treatment with furosemide, hydrochlorothiazide, monoamine oxidase inhibitors
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Topiramate
For children: Children will start on topiramate with a dosage of 0.5mg/kg in the evening, followed by 0.5mg/kg/day weekly increments until an initial target dose of 3mg/kg/day is reached.
The total daily topiramate dose for children may, not exceed 9mg/kg/day.
For adult patients: Adult patients start on topiramate with a dosage of 25mg/day in the evening, followed by weekly increments of 25 mg/day until an initial target dose of 100mg/day is reached.
The dose of topiramate may be increased to the optimal dose with weekly increments of 0.5mg/kg/day and of 25 mg/day for children and adults, respectively at the discretion of the investigator.
|
The patients will receive topiramate tablet twice daily orally up to 16 weeks.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Percentage of Participants Wiith Reduction in Number of Seizures Greater Than or Equal to 50%, During the Last 4 Months of Treatment
Tidsram: Month 1, Month 3 and Month 4
|
Month 1, Month 3 and Month 4
|
Percentage of Participants Wiith Reduction in Number of Seizures Greater Than or Equal to 75%, During the Last 4 Months of Treatment
Tidsram: Month 1, Month 3 and Month 4
|
Month 1, Month 3 and Month 4
|
Percentage of Seizure Free Participants During the Last 4 Months of Treatment
Tidsram: Month 1, Month 3 and Month 4
|
Month 1, Month 3 and Month 4
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants With Greater Than or Equal to 50%, 75% and 100% Reduction in Seizures as Per the Seizure Types (Partial, Secondarily Generalized and Generalized Tonic and Clonic Siezures) After 16 Weeks
Tidsram: Month 1, Month 3 and Month 4
|
Month 1, Month 3 and Month 4
|
|
Percentage of Participants With Greater Than or Equal to 50%, 75% and 100% Reduction in Seizures as Per the Seizure Frequency (Less Than 4, 4 to 10 and Greater Than 10) After 16 Weeks
Tidsram: Month 4
|
Month 4
|
|
General Clinical Assessment Before and After Treatment
Tidsram: Baseline (Day 0) and Month 4
|
The general clinical assessment is measured by clinical global impression scale.
The scale is used to grade the participants as very good, good, fairly good, medium and Poor before (Visit 1) and after treatment (Visit 6).
|
Baseline (Day 0) and Month 4
|
Percentage of Participants With Greater Than or Equal to 50%, 75% and 100% Reduction in Seizures With or Without Previous Treatment
Tidsram: Month 4
|
Month 4
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Studierektor: Janssen-Cilag VIETNAM Clinical Trial, Janssen-Cilag VIETNAM
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 maj 2008
Primärt slutförande (Faktisk)
1 januari 2010
Avslutad studie (Faktisk)
1 januari 2010
Studieregistreringsdatum
Först inskickad
23 augusti 2012
Först inskickad som uppfyllde QC-kriterierna
17 september 2012
Första postat (Uppskatta)
21 september 2012
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
1 maj 2013
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
26 april 2013
Senast verifierad
1 april 2013
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CR017830
- TOPMATEPY4049 (Annan identifierare: Janssen-Cilag VIETNAM)
- TOP-VN -0107 (Annan identifierare: Janssen-Cilag VIETNAM)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Topiramate
-
Johnson & Johnson Taiwan LtdAvslutad
-
Supernus Pharmaceuticals, Inc.Avslutad
-
University of CopenhagenR W Johnson Pharmaceutical Research InstituteAvslutad
-
Montefiore Medical CenterOrtho-McNeil PharmaceuticalAvslutad
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.Avslutad
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.Avslutad
-
Johnson & Johnson Pharmaceutical Research & Development...AvslutadFetma | Diabetes mellitus, typ 2 | Diabetes mellitus, vuxendebut
-
Johnson & Johnson Pharmaceutical Research & Development...AvslutadFetma | Hypertriglyceridemi | Hyperlipidemi
-
Johnson & Johnson Pharmaceutical Research & Development...AvslutadEpilepsi | Anfall | Epilepsi, partiell
-
Johnson & Johnson Pharmaceutical Research & Development...Avslutad